sPARK.
2019

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, …

The Lancet Oncology 20(6), 837–848

Wungki Park
ImmunotherapySarcomaClinical Trial
427Citations
2019Year

Related by topic

Research Program · ImmunotherapyDNA Damage Repair & PARP-ImmunotherapyResearch Program · ImmunotherapyNeoantigens & BiologicsPublication · ImmunotherapyOutcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortPublication · ImmunotherapyPembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR TrialPublication · ImmunotherapyPersonalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerJournal Club · ImmunotherapyPhase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

Local graph

Drag to pan · scroll to zoom · drag a node to move · double-click to open

Open full graph →